Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
#4PRI RANKED
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Venetoclax · Azacitidine · Acute myeloid leukemia (AML) · chemotherapy-ineligible patients · VIALE-A trial · Overall survival · complete remission with/without blood count recovery · CR/CRi · IDH1/2 mutations · Measurable residual disease (MRD) · thrombocytopenia · neutropenia · Newly diagnosed acute myeloid leukemia · Intensive chemotherapy · long-term follow-up · hazard ratio
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459